JPRN-UMIN000014486Completed未知
Efficacy and security of certolizumab pegol treatment in patients with reumatoid arthritis - Saitama East Study
Saitama East Study Group0 sites100 target enrollmentStarted: December 1, 2014Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.Patients have other rheumatic diseases. 2. Patients have malignant disorders in recent 5 years. 3.Patients have a risk for tuberculosis. 4.Patients who develpoprd bacterial infection and antibiotics were administrated within 30 days after first CPZ treatment. 5.Drug or alcohol addiction or abusers. 6.Patients who are not able to be adequately evaluated in this study. 7.Patients who have Type B viral hepatitis. 8.Patients who have nontuberculous mycobacteril infection. 9.Patients who have congestive heart failure(>II).
Investigators
Similar Trials
Completed
Not Applicable
Efficacy and safety of certolizumab pegol in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitorRheumatoid arthritisJPRN-UMIN000020154Saitama Medical University, Department of Rheumatology and Applied Immunology150
Completed
Phase 3
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque PsoriasisModerate Chronic Plaque PsoriasisSevere Chronic Plaque PsoriasisMixed Guttate/Plaque PsoriasisNCT04123795UCB Biopharma SRL49
Completed
Phase 2
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic PsoriasisModerate to Severe PsoriasisGeneralized Pustular Psoriasis and Erythrodermic PsoriasisNCT03051217UCB Biopharma S.P.R.L.127
Recruiting
Not Applicable
Certolizumab Pegol treatment with Reducing and stoppIng MEthotrexate in patients with Rheumatoid Arthritis in stable low disease activity-stateRheumatoid arthritisJPRN-jRCTs041200048Asai Shuji88
Active, not recruiting
Phase 1
Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled studyPrediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA)EUCTR2013-000337-13-PTniversitätsklinikum Erlangen156